A bone drug to prevent breast cancer in BRCA1 carriers
BRCA1 breast cancers seem to grow from cells driven by the RANK signal. Denosumab blocks it and is already used for bone. A trial is testing whether it prevents these cancers.
RANKL signalling drives progenitor expansion in BRCA1 breast tissue; the BRCA-P trial (ABCSG) randomises BRCA1 carriers to denosumab versus placebo with breast cancer incidence as the endpoint. Propose supporting completion and preparing implementation pathways for a positive result.
- Inherited risk is mostly unidentified · Most people who carry a high-risk cancer gene do not know it until they or a relative gets cancer.
Pages like this
not linked directly; found by shared links- IdeaOffer everyone at 30 a test for the cancer genes that matter
Shares PROSE consortium: preventive surgery lowers cancer and death in BRCA1 and BRCA2 carriers, Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD).
- IdeaPopulation germline screening for hereditary cancer genes with cascade testing
Shares PROSE consortium: preventive surgery lowers cancer and death in BRCA1 and BRCA2 carriers, Chemoprevention & risk-reducing surgery, Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD).
- IdeaGo back to families of women who died of ovarian cancer and offer BRCA testing
Shares Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD).
- IdeaLet clinics contact relatives directly when a cancer gene is found
Shares Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD).
- IdeaCancer interception vaccines for high-risk carriers
Shares Chemoprevention & risk-reducing surgery, Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).
- TechnologyCancer interception vaccines
Shares Chemoprevention & risk-reducing surgery, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).
- PersonVincent K. Tuohy
Shares Chemoprevention & risk-reducing surgery, Triple-negative breast cancer (TNBC).
- PersonSusan M. Domchek
Shares PROSE consortium: preventive surgery lowers cancer and death in BRCA1 and BRCA2 carriers, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).